PhotoPharmics Gets FDA Breakthrough Status for Parkinson’s PhotoTherapy
May 1, 2020
PhotoPharmics, a pioneer in specialized phototherapy, announced on April 29, that it has received FDA Breakthrough device designation for the company’s non-invasive Specialized Phototherapy Device.
“Hats off to Utah’s PhotoPharmics,” said Kelvyn Cullimore, president and CEO of BioUtah. “Earning this Breakthrough designation is a significant value driver for a privately-owned device company.”
“Our device is the first specialized phototherapy device to achieve this status,” said Kent Savage, CEO of PhotoPharmics. “Our focus is to help people with Parkinson’s improve function… we think this recognition by FDA validates our work.”
The prescription phototherapy for Parkinson’s patients is intended to be used an adjunct treatment with standard dopaminergic therapy and is designed primarily for home use.
Recent News
- Nucleus Institute Convergence Point Groundbreaking
- EDWARDS LIFESCIENCES RECEIVES FDA APPROVAL FOR AUTUS VALVE
- Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
- Owlet Announces Creation of Baby Safety Task Force to Educate, Innovate, and Advocate for Better Baby Safety Standards
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
